LAVA Therapeutics N.V. is developing a portfolio of bispecific gamma delta T cell engagers (gamma delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its proprietary Gammabody™ platform. The company’s innovative approach leverages bispecific antibodies to activate Vγ9Vδ2 T cells upon binding to membrane-expressed tumor-associated antigens. Activated Vγ9Vδ2 T cells are engaged for direct, selective tumor cell killing. The company’s lead program, LAVA-1207, is presently enrolling patients in Phase 1/2a clinical studies. The company has established a highly experienced research and development team located in Utrecht, the Netherlands and Philadelphia, USA.
September 11, 2023 at 7:00 AM EDT
August 17, 2023 at 10:00 AM EDT
February 16, 2023 at 1:00 PM EST
Data Provided by Refinitiv. Minimum 15 minutes delayed.